Esberitox tablets 3.2 mg 60 pcs.

Baptisia tinctoria – accelerates the formation of antibodies. Acts on B-lymphocytes (specific immunity).

Echinacea purpurea and Echinacea pallido – stimulate phagocytosis (nonspecific immunity).

Thuja – has antiviral effects.

To increase the body’s resistance as a supportive therapy in the complex treatment of respiratory viral colds.

Adults and children over 12 years of age should take 3-6 tablets 3 times a day.

Children aged 7 to 11 years: 2 tablets 3 times a day.

Children aged 4 to 6 years: 1-2 tablets 3 times a day.

The tablets should be taken with plenty of liquid, preferably water, or dissolved in the mouth in the morning, at lunchtime and in the evening.

Children. The drug is intended for children from 4 years of age.

Hypersensitivity to the active substances or any of the excipients of the drug. The drug should not be used in patients with progressive systemic diseases (tuberculosis and sarcoidosis); autoimmune diseases (collagenosis, multiple sclerosis); immunodeficiency states (AIDS, HIV infection); immunosuppressive states caused by the use of cytostatic drugs or immunosuppressants, for example after transplantation; hematological diseases (leukemia, agranulocytosis).

The assessment of side effects is based on the following frequency indicators: very common: ≥1/10; common: ≥1/100-1/10; uncommon: ≥1/1000-1/100; rare: ≥1/10,000-1/1000; very rare: <1/10,000; unknown: frequency cannot be estimated from the available data.

Immune system: hypersensitivity reactions, including skin rashes, itching, facial swelling, shortness of breath, decreased blood pressure.

On the part of the digestive system: abdominal pain, vomiting, diarrhea.

General disorders: dizziness.

Frequency data are not available.

If symptoms of the disease worsen or last more than 10 days, or if shortness of breath, fever, purulent or bloody discharge occurs, you should consult a doctor.

Patients with rare hereditary problems of galactose intolerance, fructose intolerance, sucrase-isomaltase deficiency, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Use during pregnancy and breastfeeding. Do not use.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms is unknown.

It has been established that the preparation from the root of Echinacea purpurea affects the activity of cytochrome-450 isoforms CYP 3A or CYP 1A2, which are involved in the metabolism of drugs. No studies have been conducted for other components of the drug Esberitox, tablets. This drug has not been sufficiently studied with regard to the above effect. Thus, the drug Esberitox, tablets should not be used together with drugs whose excretion depends on the activity of cytochrome-450 isoforms CYP 3A or CYP 1A2. There are currently no known contraindications to taking the drug Esberitox, tablets, with food and drinks. No relevant studies have been conducted with the drug.

Not marked.

At a temperature not exceeding 30 °C.